198 related articles for article (PubMed ID: 30744695)
1. Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.
Weber DG; Brik A; Casjens S; Burek K; Lehnert M; Pesch B; Taeger D; Brüning T; Johnen G;
BMC Res Notes; 2019 Feb; 12(1):77. PubMed ID: 30744695
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
3. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
[TBL] [Abstract][Full Text] [Related]
4. Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
Weber DG; Gawrych K; Casjens S; Brik A; Lehnert M; Taeger D; Pesch B; Kollmeier J; Bauer TT; Johnen G; Brüning T
Dis Markers; 2017; 2017():9280170. PubMed ID: 28321148
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.
Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD
Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
[TBL] [Abstract][Full Text] [Related]
7. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
[TBL] [Abstract][Full Text] [Related]
8. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
Jiménez-Ramírez C; Gilbert Weber D; Aguilar-Madrid G; Brik A; Juárez-Pérez CA; Casjens S; Raiko I; Brüning T; Johnen G; Cabello-López A
PLoS One; 2022; 17(10):e0275936. PubMed ID: 36240245
[TBL] [Abstract][Full Text] [Related]
9. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.
Kirschner MB; Cheng YY; Badrian B; Kao SC; Creaney J; Edelman JJ; Armstrong NJ; Vallely MP; Musk AW; Robinson BW; McCaughan BC; Klebe S; Mutsaers SE; van Zandwijk N; Reid G
J Thorac Oncol; 2012 Jul; 7(7):1184-91. PubMed ID: 22617246
[TBL] [Abstract][Full Text] [Related]
10. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
[TBL] [Abstract][Full Text] [Related]
12. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study.
Weber DG; Johnen G; Bryk O; Jöckel KH; Brüning T
PLoS One; 2012; 7(1):e30221. PubMed ID: 22253921
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study.
Mozzoni P; Ampollini L; Goldoni M; Alinovi R; Tiseo M; Gnetti L; Carbognani P; Rusca M; Mutti A; Percesepe A; Corradi M
Dis Markers; 2017; 2017():9645940. PubMed ID: 28757678
[TBL] [Abstract][Full Text] [Related]
14. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
15. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
16. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
17. The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.
Zhang C; Xia R; Zhang B; Wang H
BMC Cancer; 2018 Nov; 18(1):1110. PubMed ID: 30424721
[TBL] [Abstract][Full Text] [Related]
18. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
Santarelli L; Strafella E; Staffolani S; Amati M; Emanuelli M; Sartini D; Pozzi V; Carbonari D; Bracci M; Pignotti E; Mazzanti P; Sabbatini A; Ranaldi R; Gasparini S; Neuzil J; Tomasetti M
PLoS One; 2011 Apr; 6(4):e18232. PubMed ID: 21483773
[TBL] [Abstract][Full Text] [Related]
19. Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer.
Wang J; Yan F; Zhao Q; Zhan F; Wang R; Wang L; Zhang Y; Huang X
Sci Rep; 2017 Jun; 7(1):4150. PubMed ID: 28646161
[TBL] [Abstract][Full Text] [Related]
20. Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer.
Guo J; Liu C; Wang W; Liu Y; He H; Chen C; Xiang R; Luo Y
PLoS One; 2018; 13(7):e0200716. PubMed ID: 30048472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
